Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium turnhoutseweg, 30, b-2340 beerse, - teclistamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 90mg/ml - teclistamab 90mg - not yet assigned

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium turnhoutseweg, 30, b-2340 beerse, - teclistamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/ml - teclistamab 10mg - not yet assigned

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.